A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)
Publication
, Conference
Ross, A; Armstrong, AJ; Pieczonka, CM; Bailen, JL; Tutrone, RF; Cooperberg, MR; Pavlovich, CP; Renzulli, JF; Haynes, H; Sheikh, NA; Shore, ND
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 20, 2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 20, 2020
Volume
38
Issue
6
Location
San Francisco, CA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ross, A., Armstrong, A. J., Pieczonka, C. M., Bailen, J. L., Tutrone, R. F., Cooperberg, M. R., … Shore, N. D. (2020). A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
Ross, Ashley, Andrew J. Armstrong, Christopher M. Pieczonka, James L. Bailen, Ronald F. Tutrone, Matthew R. Cooperberg, Christian P. Pavlovich, et al. “A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
Ross A, Armstrong AJ, Pieczonka CM, Bailen JL, Tutrone RF, Cooperberg MR, et al. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.
Ross, Ashley, et al. “A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
Ross A, Armstrong AJ, Pieczonka CM, Bailen JL, Tutrone RF, Cooperberg MR, Pavlovich CP, Renzulli JF, Haynes H, Sheikh NA, Shore ND. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 20, 2020
Volume
38
Issue
6
Location
San Francisco, CA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences